TP53 and prostate neoplasm: Patnaik et al. demonstrated that cabozantinib induced CXCL12 and high mobility group box 1 (HMGB1) proteins, leading to increased neutrophil chemoattraction in the prostate tumor tissues of PTEN/p-53-decifient mice, suggesting that cabozantinib suppresses prostate tumors by activating anti-tumoral innate immunity [41].